The Gut Microbiome and Metastatic Renal Cell Carcinoma

The introduction of targeted therapy (TT) and immuno-oncology (IO) agents have revolutionized the treatment of metastatic renal cell carcinoma (mRCC). However, despite the significant improvements in survival and clinical response yielded by these agents, a significant percentage of patients still e...

Descripción completa

Detalles Bibliográficos
Autores principales: Meza, Luis, Feng, Matthew, Lee, Kyle, Sperandio, Rubens, Pal, Sumanta Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9960560/
https://www.ncbi.nlm.nih.gov/pubmed/36836036
http://dx.doi.org/10.3390/jcm12041502

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9960560/
https://www.ncbi.nlm.nih.gov/pubmed/36836036
http://dx.doi.org/10.3390/jcm12041502

Ejemplares similares